AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17596795
Drug: Hib-DPT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-DPT vaccine (3 doses)
Trial: 17596795
Drug: Hib-DPT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-DPT vaccine (2 doses)
Trial: 17596795
Drug: Hib-DPT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-DPT vaccine
Trial: 8799530
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg microenema
Trial: 8799530
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg as a 60 min i.v. continuous infusion
Trial: 8799530
Drug: Suppositories
RxNorm normalized name: Tucks Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppositories
Trial: 1600971
Drug: Stepdown regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepdown regimen of propofol (10 mg kg‐1 h‐1 for 10 min, 8 mg kg‐1 h‐1 for the next 10 min, 6 mg kg‐1 h‐1 thereafter)
Trial: 1600971
Drug: Steady rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steady rate infusion of propofol (6 mg kg‐1 h‐1)
Trial: 1600971
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Stepdown and Steady rate infusion)
Trial: 31466813
Drug: NCHT (Neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCHT (Neoadjuvant Chemohormonal Therapy)
Trial: 31466813
Drug: NHT (Neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHT (Neoadjuvant Hormonal Therapy)
Trial: 31466813
Drug: No-NT (No
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-NT (No Neoadjuvant Therapy)
Trial: 25171552
Drug: Curcuminoids (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (1500 mg/day) + piperine (15 mg/day)
Trial: 25913052
Drug: Triamcinolone ointment
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone ointment CIC
Trial: 25913052
Drug: Contractubex ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contractubex ointment CIC
Trial: 16868325
Drug: Nitroglycerin patch
RxNorm normalized name: Nitroglycerin Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patch (0.2 mg/h)
Trial: 16868325
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (adhesive patch without active ingredient)
Trial: 10962867
Drug: Ceftibuten 400
RxNorm normalized name: ceftibuten 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten 400 mg od for seven days
Trial: 10962867
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g/day i.v. for a total of 10 days
Trial: 8853769
Drug: Amoxycillin suspension
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin suspension given pre-prandially
Trial: 8853769
Drug: Amoxycillin suspension
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin suspension given post-prandially
Trial: 1377333
Drug: Paracetamol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (3 x 1000 mg over 8 h)
Trial: 6725527
Drug: Bromocriptine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5 mg orally)
Trial: 6725527
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg orally) plus Bromocriptine
Trial: 6725527
Drug: Domperidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (20 mg orally) plus Bromocriptine
Trial: 22388713
Drug: Head orthesis
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head orthesis therapy
Trial: 18693659
Drug: Bupivacaine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (2.5 mg)
Trial: 8517061
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g vigabatrin for 2 months
Trial: 8517061
Drug: titrated optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: titrated optimal dosage vigabatrin for another 2 months
Trial: 3481814
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ANG II and NA infusion
Trial: 29164797
Drug: sacubitril/valsartan (LCZ696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan (LCZ696) 200 mg twice per day, initiated and up-titrated over 3 or 6 weeks
Trial: 29164797
Drug: Gradual up-titration
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual up-titration (6 weeks) of sacubitril/valsartan
Trial: 29164797
Drug: sacubitril/valsartan (LCZ696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan (LCZ696) 200 mg twice per day
Trial: 19366965
Drug: Ranirestat 20
RxNorm normalized name: Ranirestat
DrugBank: Ranirestat (DB05327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranirestat 20 mg/day
Trial: 19366965
Drug: Ranirestat 40
RxNorm normalized name: Ranirestat
DrugBank: Ranirestat (DB05327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranirestat 40 mg/day
Trial: 16935343
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not explicitly defined, but implied as the comparison between the two doses)
Trial: 15293170
Drug: Non-invasive ventilation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive ventilation (NIV) applied for at least six hours per day in addition to standard COPD treatment.
Trial: 15293170
Drug: Standard COPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard COPD treatment (Control group).
Trial: 2813482
Drug: Cocaine infusion
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine infusion after bolus loading doses
Trial: 2813482
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion after bolus loading doses
Trial: 4586044
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol (400 mug daily, intranasally)
Trial: 31579978
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Silymarin and Doxycycline
Trial: 25327537
Drug: Tapered implants
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tapered implants (test group)
Trial: 25327537
Drug: Cylindrical implants
RxNorm normalized name: Imperata cylindrica root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cylindrical implants (control group)
Trial: 21505349
Drug: LOS100 (Losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOS100 (Losartan 100 mg q.d.)
Trial: 21505349
Drug: LOS200 (Losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOS200 (Losartan 100 mg b.i.d.)
Trial: 21505349
Drug: LOS100 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOS100 + LIS20 (Losartan 100 mg q.d. + Lisinopril 20 mg q.d.)
Trial: 17224949
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% cyclosporine A in preservative-free artificial tears
Trial: 14499682
Drug: 0.5mg dutasteride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg dutasteride and 0.4mg tamsulosin for 24 weeks followed by dutasteride monotherapy
Trial: 14499682
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of tamsulosin therapy at week 24
Trial: 9113009
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.8-1.1 g/kg daily adjusted for age)
Trial: 7690093
Drug: Atenolol 300
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 300 mg
Trial: 3527810
Drug: Treatment within
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment within 6 hours of chest pain onset
Trial: 3527810
Drug: Treatment 6
RxNorm normalized name: Earwax Treatment 6.5% Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 6 to 12 hours after chest pain onset
Trial: 24500147
Drug: Dietary calcium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary calcium intake (1000 mg Ca)
Trial: 24500147
Drug: Risk alleles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk alleles from a score of 6 WC-associated SNPs with dietary calcium intake (1000 mg Ca)
Trial: 20929598
Drug: Pranlukast (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast (225 mg, b.i.d.)
Trial: 20929598
Drug: Salmeterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (100 μg, b.i.d.)
Trial: 18356628
Drug: Lipid-lowering drug
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drug therapy
Trial: 18356628
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fibrate or nicotinic acid with LDL cholesterol-lowering drug
Trial: 18356628
Drug: LDL cholesterol-lowering
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL cholesterol-lowering drug therapy
Trial: 16038024
Drug: Oral Xeloda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Xeloda 1,000 mg/m2 administered twice daily from d 1 to 14
Trial: 16038024
Drug: Calcium folinate
RxNorm normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium folinate (CF) 200 mg/m2 as a 2-h intravenous infusion followed by 5-FU 600 mg/m2 intravenously for 4-6 h on d 1-5
Trial: 12447029
Drug: Fluoxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (up to 60 mg/day for 6 weeks, then up to 80 mg/day for 8 weeks)
Trial: 12447029
Drug: Fluoxetine responders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine responders (n = 11)
Trial: 10337457
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of fermented and unfermented aqueous extracts of Viscum album L. (Iscador Qu Spezial and Viscum album QuFrF)
Trial: 10337457
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of fermented and unfermented aqueous extracts of Viscum album L.
Trial: 9110055
Drug: Doxazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1 mg daily, increased to a maximum of 16 mg daily)
Trial: 1943500
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil (6 g per day)
Trial: 7015693
Drug: VM-26 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM-26 (30 mg/m2 iv for 5 days with 7-14 day intervals)
Trial: 7015693
Drug: VM-26 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM-26 (50 mg/m2 two injections a week for 4-6 weeks)
Trial: 28807367
Drug: Platinum therapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum therapy for OCCC
Trial: 28807367
Drug: Platinum therapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum therapy for SOC
Trial: 28807367
Drug: Consolidative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidative therapy with weekly Paclitaxel
Trial: 24300820
Drug: Glatimer acetate
RxNorm normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glatimer acetate (GA) 20 mg daily for at least 12 months
Trial: 24300820
Drug: Interferon‐Β 44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐Β 44 mg three times a week
Trial: 20422199
Drug: High-proanthocyanidin (PA)
RxNorm normalized name: grape seed proanthocyanidins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-proanthocyanidin (PA) red de-alcoholised wine (DAW) (500 mL/die, PA dose = 7 mg/kg)
Trial: 20422199
Drug: Low-proanthocyanidin rosé
RxNorm normalized name: grape seed proanthocyanidins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-proanthocyanidin rosé de-alcoholised wine (DAW) (500 mL/die, PA dose = 0.45 mg/kg)
Trial: 19478258
Drug: Doxycycline, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline, 200 mg/day for six weeks
Trial: 17960402
Drug: Choline-stabilized orthosilicic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 10 mg Si/day for 9 months
Trial: 9212590
Drug: Interferon-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b (one dose administration)
Trial: 9212590
Drug: High-dose interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interferon-alpha 2b treatment (6-month course)
Trial: 8491012
Drug: Picotamide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (300 mg t.i.d.)
Trial: 2979683
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg or 800 mg
Trial: 26197839
Drug: Intravenous sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sildenafil (single dose during cardiac catheterisation)
Trial: 25473190
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg per day for 2 weeks (2W group)
Trial: 25473190
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg per day for 4 weeks (4W group)
Trial: 21870906
Drug: Red clover
RxNorm normalized name: Red clover
DrugBank: Trifolium pratense pollen (DB15530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red clover isoflavones (80 mg, two daily capsules)
Trial: 20367823
Drug: Medication Alliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Alliance training (expert group)
Trial: 20367823
Drug: Medication Alliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Alliance training (novice group)
Trial: 10471986
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily for 11 days
Trial: 8734139
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg (morning dose), increased to 10 mg if clinically effective
Trial: 8734139
Drug: Diltiazem 180
RxNorm normalized name: diltiazem 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 180 mg (in three divided doses), increased to 240 mg if clinically effective
Trial: 6138935
Drug: Pindolol (nonselective,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (nonselective, 10 mg)
Trial: 6138935
Drug: Metoprolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (beta 1‐receptor selective, 100 mg)
Trial: 6138935
Drug: Acebutolol (cardioselective,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (cardioselective, 500 mg)
Trial: 30646532
Drug: WSP-MR (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WSP-MR (two packs a day for a total of 132 g of WSP)
Trial: 22486209
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of water before blood donation
Trial: 16369229
Drug: EZE/SIMVA (10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA (10/20 mg)
Trial: 16369229
Drug: EZE/SIMVA (10/10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA (10/10, 10/20, or 10/40 mg)
Trial: 10488363
Drug: Dexamethasone 24
RxNorm normalized name: dexAMETHasone 24 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 24 mg intramuscularly in two divided doses 24 hours apart
Trial: 8604599
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel 2 mg intravaginally
Trial: 8604599
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel 0.5 mg intracervically
Trial: 8604599
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel 1 mg intravaginally
Trial: 1757608
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol 17-propionate ointment
Trial: 3733281
Drug: Enteric-coated tablet
RxNorm normalized name: Walgreens Low Dose Aspirin 81mg Enteric-Coated Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated tablet
Trial: 6623020
Drug: Microcrystalline tablet
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline tablet
Trial: 6623020
Drug: Capsule containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing enterosoluble granules
Trial: 26879693
Drug: Target-controlled noradrenaline
RxNorm normalized name: noradrenaline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target-controlled noradrenaline infusion to manipulate blood pressure (BP) during surgery
Trial: 23292523
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg salbutamol
Trial: 21432607
Drug: Manualized dialectical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized dialectical behavioural therapy (DBT) plus methylphenidate
Trial: 21432607
Drug: Manualized dialectical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized dialectical behavioural therapy (DBT) plus placebo
Trial: 8864022
Drug: Heparin-coated CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated CPB circuits (Group HC)
Trial: 25835231
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C deficiency (biochemical depletion below 11 µmol/L)
Trial: 17521930
Drug: Asasantin (Dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asasantin (Dipyridamole 200mg/Aspirin 25mg) twice daily (group I; n=39)
Trial: 17521930
Drug: Asasantin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asasantin plus 75 mg Clopidogrel once daily (group II; n=33)
Trial: 17521930
Drug: Asasantin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asasantin plus Rheomacrodex (Dextran 40) 100g/L iv; 500 ml (group III; n=30)
Trial: 11443224
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg daily for 6 months)
Trial: 9531962
Drug: Allergen inhalation
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen inhalation (very low doses)
Trial: 7974930
Drug: Diltiazem (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (calcium channel blocker)
Trial: 2524959
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for both dipyridamole and aspirin
Trial: 2524959
Drug: Dipyridamole (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (75 mg) and aspirin (324 mg)
Trial: 2524959
Drug: Dipyridamole (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (75 mg) and placebo for aspirin
Trial: 30991614
Drug: Early high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early high-dose erythropoietin (EPO)
Trial: 28249572
Drug: Ertapenem (de-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (de-escalation therapy)
Trial: 16889454
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg once daily)
Trial: 11485511
Drug: Combined continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined continuous hormone replacement therapy (HRT)
Trial: 9926277
Drug: Moxonidine (0.3-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.3-0.4 mg/daily)
Trial: 7875640
Drug: Fasting conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting conditions (300 mg oral dose of penticainide)
Trial: 7875640
Drug: Fed conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed conditions (300 mg oral dose of penticainide)
Trial: 2460520
Drug: 40% alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% alcohol (100 ml intragastric administration)